Mark S. LeDoux, M.D., Ph.D.
Department of Neurology Department of Anatomy and Neurobiology
Dystonia and Huntington Disease Clinics
Movement Disorders Research Laboratories
The University of Tennessee Health Science Center
855 Monroe Avenue
Suite 415 Link Building
Memphis, TN 38163
Phone: (901) 448-1662
Fax: (901) 448-7440
Email: Mark S. LeDoux
- M.D. Institution: Louisiana State University School of Medicine
- Ph.D. Institution: University of Alabama, Birmingham, Department of Neuroscience
- Residency Training: University of Alabama at Birmingham; University of Tennessee Health Science Center
- Neurology - Mark S. LeDoux
- UT Medical Group - Mark S. LeDoux
- To support our research efforts in the fight against dystonia, give an online gift.
- Genetics and pathobiology of primary dystonia
- Using vertebrate and invertebrate models, human lymphoblastoid cell lines and stable transfected cell lines, we study the cellular and systems biology of dystonia-associated proteins (torsinA, THAP1, caytaxin, carbonic anhydrase 8 and epsilon-sarcoglycan).
- Genetic contributions to late-onset primary dystonia are being examined with candidate gene, genome-wide and gene expression studies.
- Mechanisms of neurodegeneration in Parkinson disease: several members of the tetrahydroisoquinoline (TIQ) family of monoamine alkaloids can be formed from dopamine or its oxidized metabolites and may be involved in the pathogenesis of monoaminergic cell death in Parkinson disease. To examine the potential role of TIQs in monoaminergic cell death, we have used enantiomeric-selective high-performance liquid chromatography with electrochemical detection, liquid chromatography with tandem mass spectroscopy, cell culture studies of neurotoxicity and assays of mitochondrial membrane potential.
- Clinical trials of therapeutic interventions for movement disorders (dystonia, Huntington disease, Parkinson disease, restless legs syndrome)
- Anatomy and computational organization of motor systems
- The neural networks mediating suprasegmental control of the blink reflex and spontaneous blinking remain poorly understood. Viral transneuronal tracing is being used to define the integrated premotor cortical and subcortical control of levator palpebrae and orbicularis oculi motoneuron activity.
- In isolation or via interactions with striatal-thalamo-cortical pathways, olivocerebellar structures play a critical role in disorders of motor control such as ataxia and dystonia. Using neurophysiological and molecular tools, we are dissecting the relative roles of individual network elements in the positive and negative signs characteristic of individual movement disorders.
Clinical Subspecialty Expertise
Adult and Pediatric Movement Disorders, Botulinum Toxin for Dystonia and Spasticity
- Ledoux MS, Dauer WT, Warner TT. Emerging common molecular pathways for primary dystonia. Mov Disord. 2013 Jun 15;28(7):968-81. doi: 10.1002/mds.25547. PubMed PMID: 23893453; PubMed Central PMCID: PMC3838975.
- Moscovich M, Ledoux MS, Xiao J, Rampon GL, Vemula SR, Rodriguez RL, Foote KD, Okun MS. Dystonia, facial dysmorphism, intellectual disability and breast cancer associated with a chromosome 13q34 duplication and overexpression of TFDP1: case report. BMC Med Genet. 2013 Jul 13;14(1):70. [Epub ahead of print] PubMed PMID: 23849371; PubMed Central PMCID: PMC3722009.
- Evidente VG, Fernandez HH, Ledoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(Â®)) in cervical dystonia. J Neural Transm. 2013 Dec;120(12):1699-707. doi: 10.1007/s00702-013-1048-3. Epub 2013 Jun 19. PubMed PMID: 23779062; PubMed Central PMCID: PMC3834167.
- Hedera P, Davis TL, Phibbs FT, Charles PD, LeDoux MS. FUS in familial essential tremor - the search for common causes is still on. Parkinsonism Relat Disord. 2013 Sep;19(9):818-20. doi: 10.1016/j.parkreldis.2013.04.009. Epub 2013 May 6. PubMed PMID: 23660545.
- Ledoux MS. Non-Parkinson movement disorders: Five new things. Neurol Clin Pract. 2013 Feb;3(1):22-29. PubMed PMID: 23634381; PubMed Central PMCID: PMC3613216.
- Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord. 2013 Sep;28(10):1407-15. doi: 10.1002/mds.25362. Epub 2013 Feb 28. PubMed PMID: 23450660.